SR 26241 | 127446-96-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: SR 26241
• 英文别名: ethyl 4-[1-(N,N-dipropylcarbamoyl)ethylamino] 7-trifluoromethyl quinoline 3-carboxylate；Ethyl 4-(1-(N,N-dipropylcarbamoyl)ethylamino)-7-trifluoromethylquinoline-3-carboxylate；ethyl 4-[[1-(dipropylamino)-1-oxopropan-2-yl]amino]-7-(trifluoromethyl)quinoline-3-carboxylate
• CAS: 127446-96-2
• 化学式: C₂₂H₂₈F₃N₃O₃
• 分子量: 439.478
• InChiKey: RRILIJHOFZMDMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  31
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  71.5
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-amino-N,N-dipropylpropanamide 、 4-氯-7-三氟甲基喹啉-3-羧酸乙酯 在 三乙胺 作用下， 以 乙醇 、 水 为溶剂， 生成 SR 26241
  参考文献：
  名称：

  4-amino quinolines and naphthyridines and their use as medicines

  摘要：

  该通用公式代表的化合物为：##STR1## 其中R.sub.1和R.sub.2从氢，C.sub.1 -C.sub.6烷基或C.sub.2 -C.sub.6烯基，苯基或苄基中选择，或者R.sub.1和R.sub.2与它们所附着的氮原子一起形成一个C.sub.4 -C.sub.8饱和杂环；R.sub.3从氢，C.sub.1 -C.sub.6烷基，苯基或C.sub.7 -C.sub.9苯基-烷基中选择；R.sub.4从氢或C.sub.1 -C.sub.4烷基中选择；R.sub.5和R.sub.6从氢或卤素，C.sub.1 -C.sub.3或烷氧基，硝基或三氟甲基中选择；Z从OH，C.sub.1 -C.sub.6烷氧基，C.sub.1 -C.sub.4烷基，苄基，C.sub.4 -C.sub.6含或不含杂原子的芳基，或NR.sub.8R.sub.9中选择，其中R.sub.8和R.sub.9从氢，C.sub.1 -C.sub.4烷基，苯基或苄基中选择；R.sub.10从氢，C.sub.1 -C.sub.4烷基或苯基中选择；n为0，1或3，p为0或1，符号A、B、C、D中的一个代表N，其他则代表CH，它们的酸加成盐和碱盐。这些化合物在心血管疾病的预防和治疗、抗过敏药物、预防和治疗感染状态以及焦虑症的治疗中有用。

  公开号：

  US05026711A1

文献信息

• MENDES, ETIENNE;VERNIERES, JEAN-CLAUDE;KEANE, PETER EUGENE;BACHY, ANDRE
  作者：MENDES, ETIENNE、VERNIERES, JEAN-CLAUDE、KEANE, PETER EUGENE、BACHY, ANDRE

  DOI：——

  日期：——
• US5026711A
  申请人：——

  公开号：US5026711A

  公开（公告）日：1991-06-25
• 4-amino quinolines and naphthyridines and their use as medicines
  申请人：Sanofi

  公开号：US05026711A1

  公开（公告）日：1991-06-25

  Compounds represented by the general formula: ##STR1## in which R.sub.1 and R.sub.2 are selected from hydrogen, C.sub.1 -C.sub.6 alkyl or C.sub.2 -C.sub.6 alkenyl , phenyl or benzyl or R.sub.1 and R.sub.2 form together with the nitrogen atom to which they are attached a C.sub.4 -C.sub.8 saturated heterocycle, R.sub.3 is selected from hydrogen, C.sub.1 -C.sub.6 alkyl, phenyl or C.sub.7 -C.sub.9 phenyl-alkyl, R.sub.4 is selected from hydrogen or C.sub.1 -C.sub.4 alkyl, R.sub.5 and R.sub.6 are selected from hydrogen or halogen, C.sub.1 -C.sub.3 or alkoxy, nitro or trifluoromethyl; Z is selected from OH, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.4 alkyl, benzyl, C.sub.4 -C.sub.6 aryl with or without a heteroatom, or NR.sub.8 R.sub.9, R.sub.8 and R.sub.9 being selected from hydrogen, C.sub.1 -C.sub.4 alkyl, phenyl or benzyl; R.sub.10 is selected from hydrogen, C.sub.1 -C.sub.4 alkyl or phenyl; n is 0, 1 or 3, p is 0 or 1 and one of the symbols A, B, C, D represents N and the others CH or A, B, C, D all represent CH and their acid addition salts, and their salts with bases. The compounds are useful in the prevention and treatment of cardiovascular diseases, as anti-allergic drugs, in the prevention and treatment of infectious states, and for the treatment of anxiety.

  该通用公式代表的化合物为：##STR1## 其中R.sub.1和R.sub.2从氢，C.sub.1 -C.sub.6烷基或C.sub.2 -C.sub.6烯基，苯基或苄基中选择，或者R.sub.1和R.sub.2与它们所附着的氮原子一起形成一个C.sub.4 -C.sub.8饱和杂环；R.sub.3从氢，C.sub.1 -C.sub.6烷基，苯基或C.sub.7 -C.sub.9苯基-烷基中选择；R.sub.4从氢或C.sub.1 -C.sub.4烷基中选择；R.sub.5和R.sub.6从氢或卤素，C.sub.1 -C.sub.3或烷氧基，硝基或三氟甲基中选择；Z从OH，C.sub.1 -C.sub.6烷氧基，C.sub.1 -C.sub.4烷基，苄基，C.sub.4 -C.sub.6含或不含杂原子的芳基，或NR.sub.8R.sub.9中选择，其中R.sub.8和R.sub.9从氢，C.sub.1 -C.sub.4烷基，苯基或苄基中选择；R.sub.10从氢，C.sub.1 -C.sub.4烷基或苯基中选择；n为0，1或3，p为0或1，符号A、B、C、D中的一个代表N，其他则代表CH，它们的酸加成盐和碱盐。这些化合物在心血管疾病的预防和治疗、抗过敏药物、预防和治疗感染状态以及焦虑症的治疗中有用。